Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times

Group 1: Market Overview - J.P. Morgan estimates a 60% chance of a recession in 2025 due to trade wars and tariffs, putting the current bull market at risk [1] - The recent market downturn was influenced by trade wars and uncertainty, leading to corrections in major indexes despite an initial post-election rise [2] Group 2: AbbVie Company Analysis - AbbVie has transformed from relying heavily on Humira, which accounted for 58% of sales in 2019 and peaked at $21 billion in 2022, to a more diversified portfolio [6][9] - The acquisition of Allergan for $63 billion in 2020 significantly reduced reliance on Humira and expanded AbbVie's product offerings [7][9] - AbbVie generated approximately $15 billion in revenue from Allergan products in 2024, showcasing the success of the acquisition [9] - In 2024, AbbVie acquired ImmunoGen and Cerevel Therapeutics for $10 billion and $9 billion, respectively, with the ImmunoGen deal showing promise through its ovarian cancer drug Elahere [10] - Sales from AbbVie's internally developed drugs Skyrizi and Rinvoq reached $17.7 billion in 2024, marking a 51% increase over 2023 [11] Group 3: Financial Performance - AbbVie's first-quarter 2025 earnings showed an 8% revenue growth to $13.3 billion, driven by Skyrizi, Rinvoq, and neuroscience gains [13] - The company raised its sales guidance for 2025 by $700 million to $60 billion, reflecting a 7% increase over 2024 [13] Group 4: Investment Considerations - AbbVie is viewed as a safe investment with a solid dividend yield of 3.5%, having increased its dividend annually since 2013 [14] - Analysts are predominantly bullish on AbbVie, with 17 buy or strong buy ratings and no sell ratings, indicating confidence in the stock's stability [15]